IMU

2.08%

4.9¢ imugene limited

Ann: FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA, page-33

First 33 Last

Share
Profile

Follow
slick

14,525 Posts.

7766

13/12/21

11:59

Post #: 58253994
Share

Originally posted by PilbaraBoy: ↑

You'd think so right plovagurl????

But remember - this is the pathetic farce known as the ASX that we are dealing with (as well as imbecile so called "investors" that barely understand what Telstra & Woolworths do, let alone a biotech company researching cutting-edge cancer immuno-oncology therapies.)

Let me recap: In just the past 4 weeks Imugene has:

* Announced a Clinical Trial Agreement with Merck & Pfizer.
* Obtained S&P admittance into the ASX200.
* Received $6 million in cash (via conversion of 150 million IMUOB options).
* Received FDA IND approval for its second Oncolytic Virus (Vaxinia).
* Received FDA IND approval for an additional Phase 2 clinical trial for HER-Vaxx

Any other biotech company, on any other index in the world (with a comparable share price & market cap to Imugene) would have seen it's share price hit $1.00 as result of all this cumulative news.

Only 1 in 10,000 drug applications receives an FDA IND approval. For Imugene to receive 2 in a single day is truly remarkable.

But here, on this joke known as the "ASX", sitting now at a share price of 52 cents, we are actually 12% BELOW the 59 cents we were at before we received the first monumental news of the Merck & Pfizer agreement???????????

How the hell is that possible?

Are the pathetic leaches trading their shares to make a measley2 cents profit responsible? No, those cretins don't have that much sway in the market. So that must mean that it's institutional/broker driven games that are reducing & capping the share price.

Whatmighthaveben probably hit the nail on the head when he wrote on the weekend that it was coming time for Imugene to leave the ASX and list on the NASDAQ. A company like Imugene with it's priceless IP, current cash reserves of AUD$120 million, and huge pipeline of FDA-approved drug candidates - would be worth at least USD$10 Billion (AUD$14 Billion) ... or AUD$2.30 a share.

Congratulations to Leslie, Paul and the tireless IMU team for today's incredibly amazing news.

Expand

Hahaha.

IMU Price at posting: 52.0¢ Sentiment: None Disclosure: Held
24 Upvote

0 Great analysis

Reply

Top Stories

TIG

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

CXU

Cauldron Energy reports "excellent" uranium assays in latest drill run

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

IMA

Issues emerging as Australian companies tackle critical minerals challenge

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

NWH

NRW Holdings inks $109M deal with BHP for works at Jimblebar

A3D

Defence MOU for propulsion systems pushes Aurora Lab shares higher

RAG

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

SHN

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

There are more pages in this discussion • 10 more messages in this thread...

First 33 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.9¢		Change 0.001(2.08%)		Mkt cap ! $364.4M

Open	High	Low	Value	Volume
4.8¢	4.9¢	4.8¢	$179.8K	3.692M

Buyers (Bids)

No.	Vol.	Price($)
62	8124186	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.9¢	3070575	9

View Market Depth

No.	Vol.	Price($)
56	7804777	0.048
47	5437350	0.047
38	3197542	0.046
58	3766545	0.045
11	1019564	0.044

Price($)	Vol.	No.
0.049	2050167	7
0.050	5223480	23
0.051	4434080	10
0.052	2536519	9
0.053	1966973	9

Last trade - 16.10pm 11/10/2024 (20 minute delay)

IMU (ASX) Chart

Ann: FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA, page-33

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Cauldron Energy reports "excellent" uranium assays in latest drill run

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

Issues emerging as Australian companies tackle critical minerals challenge

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

NRW Holdings inks $109M deal with BHP for works at Jimblebar

Defence MOU for propulsion systems pushes Aurora Lab shares higher

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA, page-33

Top Stories

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Cauldron Energy reports "excellent" uranium assays in latest drill run

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

Issues emerging as Australian companies tackle critical minerals challenge

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

NRW Holdings inks $109M deal with BHP for works at Jimblebar

Defence MOU for propulsion systems pushes Aurora Lab shares higher

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News